Alexion Pharmaceuticals’ Rhode Island manufacturing facility (ARIMF) in Smithfield has been approved by the FDA as a second source of commercial supply for Soliris. The EMA had approved ARIMF as a second source of supply for Soliris in the EU earlier this year. The company will maintain its agreement with its long-time contract manufacturer and, through either source, can now meet all of the forecasted commercial and clinical needs for Soliris. Additionally, Alexion has applied for regulatory ap...